Sometimes a spec stock turns out to be more right than even Cramer imagined.
That's certainly the case with NPS Pharma, an orphan drug maker, whose stock has exploded.
When Cramer talked with the CEO on Mad Money early in the year he noted the potential. At the time said the stock seemed cheap in light of the promising pipeline. "I think we may be looking a real opportunity," he said on January 7th. (Click here to go to Cramer: Real Opportunity in This Drug Maker)
How right Cramer was.
As it turned out, "NPS had some incredible success with its lead drug, Gattex for short-bowel syndrome, a rare condition where the intestines can't properly absorb nutrients and patients must therefore be fed through a tube, intravenously, for 12 hours a day."
Cramer said the drug has been so effective that some patients who take Gattex can go off the IV all together. This drug allows their bodies to process food once again.